Merit Medical Systems (MMSI) FDA Approvals $66.99 -0.52 (-0.77%) Closing price 04:00 PM EasternExtended Trading$66.97 -0.02 (-0.03%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Merit Medical Systems' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Merit Medical Systems (MMSI). Over the past two years, Merit Medical Systems has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as WRAPSODY. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. WRAPSODY FDA Regulatory Events WRAPSODY is a drug developed by Merit Medical Systems for the following indication: Cell-Impermeable Endoprosthesis (CIE). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Enrollment Update - August 18,2025Enrollment Update Drug: WRAPSODYAnnounced Date: August 18, 2025Indication: Cell-Impermeable Endoprosthesis (CIE).AnnouncementMerit Medical Systems announced today the successful enrollment of the first patient in the WRAP North America registry.AI SummaryMerit Medical Systems announced the first patient enrollment in its WRAP North America registry. The study will gather safety and effectiveness data on the WRAPSODY CIE, which restores vascular access in hemodialysis patients with vein narrowing or blockage. Enrollment began at Bluff City Vascular in Memphis. The registry aims to enroll up to 250 patients in the U.S. and Canada, tracking outcomes over three years after treatment with the WRAPSODY CIE. Omar Davis, MD, Medical Director at Bluff City Vascular, said the registry offers a key opportunity to assess the device’s potential to optimize dialysis care. David J. Dexter II, MD, National Principal Investigator, said evaluating the WRAPSODY CIE’s performance will guide its broader clinical use. Merit CEO Fred P. Lampropoulos called the first enrollment an important step in building robust evidence and advancing technology to improve dialysis care.Read Announcement Merit Medical Systems FDA Events - Frequently Asked Questions Has Merit Medical Systems received FDA approval? As of now, Merit Medical Systems (MMSI) has not received any FDA approvals for its therapy in the last two years. What drugs has Merit Medical Systems submitted to the FDA? In the past two years, Merit Medical Systems (MMSI) has reported FDA regulatory activity for WRAPSODY. What is the most recent FDA event for Merit Medical Systems? The most recent FDA-related event for Merit Medical Systems occurred on August 18, 2025, involving WRAPSODY. The update was categorized as "Enrollment Update," with the company reporting: "Merit Medical Systems announced today the successful enrollment of the first patient in the WRAP North America registry." What conditions do Merit Medical Systems' current drugs treat? Currently, Merit Medical Systems has one therapy (WRAPSODY) targeting the following condition: Cell-Impermeable Endoprosthesis (CIE).. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Harrow FDA EventsOrganon & Co. FDA EventsActuate Therapeutics FDA EventsAlterity Therapeutics FDA EventsErnexa Therapeutics FDA EventsKymera Therapeutics FDA EventsMicrobot Medical FDA EventsPalisade Bio FDA EventsRedhill Biopharma FDA EventsScienture FDA EventsTG Therapeutics FDA EventsGenmab A/S FDA EventsMediciNova FDA EventsMetaVia FDA EventsNeurocrine Biosciences FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Align Technology FDA Events Haemonetics FDA Events QuidelOrtho FDA Events Cerus FDA Events Anika Therapeutics FDA Events Cardinal Health FDA Events Becton, Dickinson and Company FDA Events Jazz Pharmaceuticals FDA Events Exelixis FDA Events BridgeBio Pharma FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:MMSI last updated on 8/19/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredForbes calls this a "golden era" for retirement incomeForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLive demo of Elon Musk’s AI agentJeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...Brownstone Research | SponsoredNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merit Medical Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merit Medical Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Enrollment Update - August 18,2025Enrollment Update Drug: WRAPSODYAnnounced Date: August 18, 2025Indication: Cell-Impermeable Endoprosthesis (CIE).AnnouncementMerit Medical Systems announced today the successful enrollment of the first patient in the WRAP North America registry.AI SummaryMerit Medical Systems announced the first patient enrollment in its WRAP North America registry. The study will gather safety and effectiveness data on the WRAPSODY CIE, which restores vascular access in hemodialysis patients with vein narrowing or blockage. Enrollment began at Bluff City Vascular in Memphis. The registry aims to enroll up to 250 patients in the U.S. and Canada, tracking outcomes over three years after treatment with the WRAPSODY CIE. Omar Davis, MD, Medical Director at Bluff City Vascular, said the registry offers a key opportunity to assess the device’s potential to optimize dialysis care. David J. Dexter II, MD, National Principal Investigator, said evaluating the WRAPSODY CIE’s performance will guide its broader clinical use. Merit CEO Fred P. Lampropoulos called the first enrollment an important step in building robust evidence and advancing technology to improve dialysis care.Read Announcement
Free MMSI Stock Alerts